On Apr. 10, 2020, Eli Lilly announced it had entered into an agreement with the National Institute of Allergy and Infectious Diseases, to study baricitinib as an arm in NIAID’s Adaptive COVID-19 Treatment Trial. The study will investigate the efficacy and safety of baricitinib as a potential treatment for hospitalized patients diagnosed with COVID-19, beginning in April in the U.S. with a planned expansion to additional sites including Europe and Asia. Results are expected within the next two months.